Predicting recurrence in high-risk hormone receptor-positive breast cancer patients receiving extended endocrine therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify predictors for the recurrence of high-risk hormone receptor-positive breast cancer in patients who have completed a standard 5-year endocrine therapy regimen. It focuses on patients who meet specific high-risk criteria, such as tumor size and lymph node involvement, to evaluate the effectiveness of extended endocrine therapy with aromatase inhibitors. The study will analyze data from various hospitals to determine the long-term outcomes and recurrence rates in this patient population. By understanding these predictors, the study seeks to improve treatment strategies for patients at risk of recurrence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* early-stage invasive breast cancer positive for estrogen receptor and / or progesterone receptor is pathologically confirmed;
* patients who have completed standard endocrine therapy for 5 years without recurrence and metastasis;
* 18-70 years old;
* patients with one of the following six manifestations: KI67 ≥ 30%; tumor size \> 2 cm; positive lymph nodes; histological grade III; vascular cancer thrombus; HER-2 gene overexpression or amplification.

Exclusion Criteria:

* with a history of other malignancies;
* patients who have severe abnormalities in important organs, such as the heart, liver, and kidney or who cannot be tolerant to extended treatment due to poor constitution;
* patients with severe osteoporosis or dyslipidemia, or those who cannot tolerate endocrine therapy ;
* patients who have participated in other clinical trials.

Where it's running

• Cancer Hospital Affiliated to Harbin Medical University
  Harbin, Heilongjiang, China Recruiting
• The Second Hospital of Jilin University
  Changchun, Jilin, China Recruiting
• Dalian Municipal Central Hospital
  Dalian, Liaoning, China Recruiting
• Panjin Liaohe Oilfield Gem Flower Hospital
  Panjin, Liaoning, China Recruiting
• Shengjing Hospital affiliated to China Medical University
  Shenyang, Liaoning, China Recruiting
• Shengjing Hospital of China Medical University
  Shenyang, Liaoning, China Recruiting

Study contacts

• Principal investigator: Jin-Qi Xue — Shengjing Hospital
• Study coordinator: Cai-Gang Liu, MD
• Email: angel-s205@163.com
• Phone: 18940254967

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.